Elderberry

Elderberry (Sambucus nigra) is a potent immunostimulant that increases cytokine production including TNF-alpha, IL-6, IL-1-beta, and activates macrophage and natural killer cell function. This immunostimulatory activity pharmacodynamically opposes immunosuppressive therapy used in transplant patients and those with autoimmune diseases, risking rejection episodes or disease flares.

Elderberry is contraindicated in transplant patients on immunosuppressive therapy. Patients with autoimmune diseases (rheumatoid arthritis, lupus, IBD) should avoid elderberry and discuss use with their specialist. If inadvertent co-administration is identified, monitor for signs of rejection or autoimmune flare.

Elderberry extract has demonstrated antidiabetic properties in vitro and in animal models via activation of peroxisome proliferator-activated receptor gamma (PPAR-gamma), stimulation of insulin-dependent glucose uptake, and inhibition of alpha-glucosidase. Concurrent use with antidiabetic medications creates additive hypoglycemic risk.

Monitor blood glucose more frequently when diabetic patients add elderberry supplementation. Educate patients on hypoglycemia symptoms. Dose adjustment of antidiabetic agents may be required. Elderberry supplementation should be used cautiously in insulin-dependent diabetics.

Elderberry has documented diuretic properties in clinical studies, promoting renal water and sodium excretion. Additive diuretic effects with loop or thiazide diuretics may cause dehydration and electrolyte imbalances including hyponatremia and hypokalemia.

Advise patients on diuretics to use elderberry cautiously. Monitor for symptoms of dehydration (thirst, dizziness, muscle cramps) and electrolyte imbalance. Ensure adequate fluid and electrolyte intake. Use lower elderberry doses when diuretics are co-prescribed.

Elderberry may have mild antiplatelet and anticoagulant effects through anthocyanin-mediated platelet inhibition. Combined with warfarin or other anticoagulants, there is a potential for additive bleeding risk. The clinical significance is likely low at typical elderberry doses but theoretical at high supplementation levels.

Advise patients on warfarin to inform their clinician if using elderberry supplements. Monitor INR if high doses are used. Recommend discontinuation 1 week prior to elective surgery as a precautionary measure. Elderberry syrups and gummies likely pose lower risk than concentrated extracts.

A published case report describes possible interaction between elderberry and pazopanib (a multikinase inhibitor) resulting in severe nausea, diarrhea, and gastrointestinal toxicity. High concentrations of elderberry extract have demonstrated inhibition of CYP3A4 in vitro, which could increase plasma levels of CYP3A4-substrate chemotherapy agents. Elderberry's immunostimulatory effects may also interfere with checkpoint inhibitor immunotherapy.

Oncology patients should consult their oncologist before using elderberry supplements. Avoid elderberry during active chemotherapy, especially with CYP3A4-sensitive agents (pazopanib, sunitinib, imatinib) and immunotherapy. Elderberry use may mask or exacerbate treatment-related immunological effects.

Elderberry anthocyanins (cyanidin-3-sambubioside) inhibit influenza neuraminidase by blocking active site segments, complementing oseltamivir neuraminidase inhibition. Elderberry also inhibits viral hemagglutinin glycoprotein attachment to host cells, providing a second independent antiviral mechanism. No pharmacokinetic interaction is expected as oseltamivir has minimal CYP450 involvement. This dual-mechanism complementarity may provide additive antiviral benefit.

Elderberry may be used alongside oseltamivir for influenza management with a favorable safety profile. No pharmacokinetic interaction is expected. Elderberry should be started within 48 hours of symptom onset for optimal effect, mirroring oseltamivir timing. Clinical synergy in rigorous human trials has not yet been established; the combination should be regarded as complementary rather than proven superior.

Elderberry upregulates pro-inflammatory cytokines including TNF-alpha, IL-1-beta, IL-6, IL-8, and IFN-gamma via NF-kB pathway activation and macrophage/dendritic cell stimulation. Cytokine-targeting biologics (tocilizumab blocks IL-6R; baricitinib/tofacitinib inhibit JAK1/2 mediating cytokine signalling) suppress this exact cytokine cascade in inflammatory diseases. Concurrent elderberry may pharmacodynamically oppose these biologics, potentially reducing their efficacy in rheumatoid arthritis, cytokine release syndrome, or COVID-19 hyperinflammation.

Patients on cytokine-targeting biologics or JAK inhibitors for autoimmune or inflammatory conditions should avoid elderberry supplements. The pro-inflammatory cytokine-inducing properties of elderberry are directly antagonistic to these drugs. Patients should disclose elderberry use to rheumatologists or treating specialists. In cytokine storm scenarios, elderberry-related cytokine upregulation may be actively harmful.

Elderberry flowers and berries contain quercetin, rutin, and anthocyanins that inhibit COX enzymes and reduce pro-inflammatory eicosanoid production, overlapping mechanistically with NSAID pharmacology. Combined use may produce additive anti-inflammatory and analgesic effects. At typical doses this synergy may be clinically useful in acute upper respiratory infections with inflammation, but long-term concurrent use carries a theoretical additive risk of GI mucosal effects and mild antiplatelet activity.

The combination of elderberry and NSAIDs is generally of low clinical concern at typical doses and may provide complementary anti-inflammatory benefits in acute respiratory infections. Advise patients on chronic NSAID therapy to limit elderberry use to acute illness episodes. Monitor for GI discomfort. No pharmacokinetic interaction is anticipated.